Verastem, Inc. Files 8-K: Regulation FD Disclosure & Other Events

Ticker: VSTM · Form: 8-K · Filed: Jan 23, 2025 · CIK: 1526119

Verastem, INC. 8-K Filing Summary
FieldDetail
CompanyVerastem, INC. (VSTM)
Form Type8-K
Filed DateJan 23, 2025
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: disclosure, financials, regulation-fd

Related Tickers: VSTM

TL;DR

Verastem (VSTM) filed an 8-K on Jan 14th covering Reg FD, other events, and financials.

AI Summary

On January 14, 2025, Verastem, Inc. filed an 8-K report detailing a Regulation FD Disclosure and Other Events. The filing also includes Financial Statements and Exhibits. The company is incorporated in Delaware and headquartered in Needham, MA.

Why It Matters

This 8-K filing provides important updates and disclosures from Verastem, Inc. to the public, ensuring transparency for investors regarding company events and financial information.

Risk Assessment

Risk Level: low — This filing is a standard 8-K report for disclosures and does not indicate any immediate or significant negative events.

Key Numbers

Key Players & Entities

FAQ

What specific events are disclosed under Regulation FD?

The filing indicates a Regulation FD Disclosure, but the specific details of the disclosure are not provided in the provided text snippet.

What are the 'Other Events' mentioned in the filing?

The filing lists 'Other Events' as an item, but the specific nature of these events is not detailed in the provided text.

When was the earliest event reported in this 8-K filing?

The earliest event reported is dated January 14, 2025.

Where are Verastem, Inc.'s principal executive offices located?

Verastem, Inc.'s principal executive offices are located at 117 Kendrick Street, Suite 500, Needham, MA 02494.

What is Verastem, Inc.'s SEC File Number?

Verastem, Inc.'s SEC File Number is 001-35403.

Filing Stats: 499 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2025-01-23 07:42:54

Key Financial Figures

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On January 23, 2025, Verastem, Inc. (the "Company") posted its updated corporate presentation on its website, a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

01 Other Events

Item 8.01 Other Events. As previously disclosed, in August 2023, the Company entered into a collaboration and option agreement with GenFleet Therapeutics (Shanghai), Inc. ("GenFleet") pursuant to which GenFleet granted the Company options to obtain exclusive development and commercialization rights worldwide outside of mainland China, Hong Kong, Macau, and Taiwan for up to three oncology programs targeting RAS pathway driven cancers (the "GenFleet Options"). On January 14, 2025, the Company exercised its GenFleet Option with respect to VS-7375, an oral and selective KRAS G12D (ON/OFF) inhibitor.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits Exhibit No. Description 99.1 Investor Presentation, dated January 23, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VERASTEM, INC. Dated: January 23, 2025 By: /s/ Daniel W. Paterson Daniel W. Paterson President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing